Schizophrenia Research
Volume 115, Issue 2 , Pages 115-120 , December 2009

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

  • Leslie Citrome

      Affiliations

    • Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    • New York University School of Medicine, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Tel.: +1 845 398 5595; fax: +1 845 398 5483.
    • ,
  • Christopher Reist

      Affiliations

    • University of California, Irvine, CA, USA
    • ,
  • Liisa Palmer

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
    • ,
  • Leslie B. Montejano

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
    • ,
  • Gregory Lenhart

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
    • ,
  • Brian Cuffel

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • James Harnett

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • Kafi N. Sanders

      Affiliations

    • Pfizer Inc., New York, NY, USA

Received 30 July 2009 ,Revised 12 September 2009 ,Accepted 17 September 2009.

References 

  1. Citrome L. Using oral ziprasidone effectively: the food effect and dose–response. Adv Ther. 2009;Aug 8. 26 (8), 739–748
  2. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol. 2005;25(4):388–391
  3. Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv. 2007;58(1):11
  4. Citrome L, Reist C, Palmer L, Montejano L, Cuffel B, Harnett J, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder. In: New Research Poster NR6-105. 161st Annual Meeting of the American Psychiatric Association, Washington, DC. 2008;May 4–8
  5. Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry. 2009;70(7):975–982
  6. Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B, et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr. Res. 2009;108(1–3):238–244
  7. Citrome L, Yang R, Glue P, Karayal ON. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr. Res. 2009;111(1–3):39–45
  8. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004;24(2):192–208
  9. Deutschman DA, Deutschman DH. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders. J. Clin. Psychopharmacol. 2007;27(5):513–514
  10. Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, cross-over trial. J. Clin. Psychiatry. 2009;70(1):58–62
  11. Hamelin BA, Allard S, Laplante L, Miceli J, Wilner KD, Tremblay J, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18(1):9–15
  12. Joyce AT, Harrison DJ, Loebel AD, Carter CT, Ollendorf DA. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr. Res. 2006;83(2–3):285–292
  13. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097
  14. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry. 2001;50(11):873–883
  15. Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J. Psychiatr. Pract. 2004;10(4):227–232
  16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N. Engl. J. Med. 2005;353(12):1209–1223
  17. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry. 2004;161(5):818–825
  18. Mech AW. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. J. Clin. Psychopharmacol. 2008;28(2):240–241
  19. Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol. Bull. 2007;40(3):58–68
  20. Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr. Res. 2006;83(2–3):277–284
  21. Pfizer . Geodon: US Package Insert for Geodon (Ziprasidone HCl) and Geodon (Ziprasidone Mesylate) for Injection, LAB-0272-2.0. 2007;Available at: http://www.pfizer.com/files/products/uspi_geodon.pdf. Accessed 2008 June 2
  22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55
  23. Rosenfield PJ, Girgis RR, Gil R. High-dose ziprasidone-induced acute dystonia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(2):546–547

PII: S0920-9964(09)00442-3

doi: 10.1016/j.schres.2009.09.023

Schizophrenia Research
Volume 115, Issue 2 , Pages 115-120 , December 2009

Article Tools

* Image Usage & Resolution